RE-DUAL PCI Post Hoc: Dabigatran Dual Therapy ‘Markedly’ Reduced Early Bleeding Risk in AFib Patients Undergoing PCI vs. Triple Warfarin Regimen
The oral anticoagulant dabigatran plus a P2Y12 inhibitor was found to “markedly” reduce the risk of early bleeding in patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention (PCI) compared to warfarin triple therapy, according to a new post hoc analysis funded by dabigatran manufacturer Boehringer Ingelheim.